• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$33.38 $0.05 (0.15%)

REAL-TIME: Last trade at

Forest Laboratories, Inc.

NYSE:FRX

Jump to this page for:

Related Resources

Forest and Almirall to Present Aclidinium Bromide Clinical Data at the American Thoracic Society (ATS) International Conference

5/18/2012 by Business Wire

Analyst Research on Teva Pharmaceutical Industries Limited and Forest Laboratories Inc. - Mixed Results for Drug Manufacturers

5/16/2012 by StockHouse

Analyst Research on Teva Pharmaceutical Industries Limited and Forest Laboratories Inc. - Mixed Results for Drug Manufacturers

5/16/2012 by StockWatch

Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week® 2012

5/14/2012 by Business Wire

Accelrys to hold a user group meeting

5/7/2012 by Theflyonthewall.com

Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results from Phase 3 Trials at American Psychiatric Association (APA) Annual Meeting

5/4/2012 by PharmiWeb.com - UK

AstraZeneca Searches For Answers (AZN, AMGN, FRX, AMLN)

5/3/2012 by Investopedia

Earnings Scorecard: Forest Labs - Analyst Blog

5/2/2012 by NASDAQ

Earnings Scorecard: Forest Labs

5/2/2012 by Zacks Equity Research Analyst Blog

What's Next for Carl Icahn?

4/30/2012 by CNBC Video

Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis And United Therapeutics

4/28/2012 by Biocompare

Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients With Major Depressive Disorder

4/27/2012 by BioSpace

Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics

4/27/2012 by PR Newswire

Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics - Press Releases

4/27/2012 by Zacks Investment Research

UPDATE - Auriga Initiates Coverage on Forest Laboratories (FRX); Lack of Near Term Catalysts Keep Us Sidelined

4/26/2012 by StreetInsider.com

Forest Labs initiated with a Hold at Auriga

4/26/2012 by Theflyonthewall.com

Forest, Pierre Fabre announce 3rd positive Phase III study for Levomilnacipran

4/26/2012 by Theflyonthewall.com

Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients with Major Depressive Disorder

4/26/2012 by PharmiWeb.com - UK

Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients with Major Depressive Disorder

4/26/2012 by Business Wire

AstraZeneca looking at for possible takeover candidates, Bloomberg says

4/25/2012 by Theflyonthewall.com

Yet Another Delay for Forest Labs - Analyst Blog

4/24/2012 by Zacks Investment Research

Yet Another Delay for Forest Labs - Analyst Blog

4/24/2012 by NASDAQ

Yet Another Delay for Forest Labs

4/24/2012 by Zacks Equity Research Analyst Blog

Ironwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012

4/23/2012 by Business Wire

Cantor Fitzgerald Maintains a 'Buy' on Forest Laboratories (FRX); Raising PT and Estimates

4/18/2012 by StreetInsider.com

Forest Laboratories' CEO Discusses Q4 2012 Results - Earnings Call Transcript

4/18/2012 by Seeking Alpha

Forest Labs risk/reward unfavorable into FDA decision, says Piper Jaffray

4/18/2012 by Theflyonthewall.com

Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Continued Growth Challenges, But There Is A Success Factor

4/18/2012 by StreetInsider.com

Forest Laboratories, Inc. to Host Investor Meeting to Review Company’s Late-Stage Product Development Pipeline and Commercialization Strategy

4/18/2012 by PharmiWeb.com - UK

Forest Laboratories, Inc. to Host Investor Meeting to Review Company’s Late-Stage Product Development Pipeline and Commercialization Strategy

4/17/2012 by Business Wire

Forest Hit by Lexapro Generics

4/17/2012 by Zacks Equity Research Analyst Blog

Forest Hit by Lexapro Generics - Analyst Blog

4/17/2012 by Zacks Investment Research

Forest Laboratories - FRX - Earnings per share equaled $0.72 in the Q4 FY12

4/17/2012 by FutureSource.com

Forest Laboratories Q4 Profit Slumps On Lower Lexapro Sales - Update

4/17/2012 by RTTNews

Forest Laboratories (FRX) Guides 2013 Above Consensus After 4Q Beat

4/17/2012 by iStockAnalyst

Forest Laboratories, Inc. (FRX) Tops Q4 EPS by 8c; Guides FY13 Above

4/17/2012 by StreetInsider.com

Forest Labs reports Q4 Namenda sales $393.1M

4/17/2012 by Theflyonthewall.com

Forest Labs sees FY13 adjusted EPS $1.20c-$1.35, consensus $1.11

4/17/2012 by Theflyonthewall.com

Forest Labs reports Q4 adjusted EPS 78c, consensus 70c

4/17/2012 by Theflyonthewall.com

Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2012 Earnings Per Share of $0.72 Including $0.06 Per Share of Acquisition Amortization

4/17/2012 by Business Wire
See More Articles...